Revisiting the role of p53 in primary and secondary glioblastomas

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4633-4639

  Nagpal, Julie ^a   Jamoona, Amrith ^a   Gulati, Nicholas D ^a   Mohan, Avinash ^a   Braun, Alex ^a   Murali, Raj ^a   Jhanwar Uniyal, Meena ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cytoplasmic; GBM; Nuclear; p53; Perivascular; VEGF

Indexed keywords

CULLIN; PROTEIN CULLIN 7; PROTEIN P53; PROTEIN PARC; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; VASCULARIZATION;

ADULT; AGED; BRAIN NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845952225     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Legler JM, Gloeckler Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS and Linet MS: Response: re: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 92: 77A-78A, 2000.
2. Demuth T and Berens ME: Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70: 217-228, 2004.
3. Kleihues P, Burger PC, Collins WP, Newcomb EW, Ohgaki H and Cavenee WK: Glioblastoma. In: Kleihues P and Cavenee WK editors. Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press, pp. 29-39, 2000.
4. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
5. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97: 6242-6244, 2000.
6. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 25: 1-7, 2005.
7. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
8. Rich JN and Bigner DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3: 430-446, 2004.
9. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
10. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO and Israel MA: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102: 5814-5819, 2005.
11. Mischel PS, Nelson SF and Cloughesy TF: Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther 2: 242-247, 2003.
12. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W and Sawaya R: Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 10: 212-221, 2004.
13. Tanwar MK, Gilbert MR and Holland EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62: 4364-4368, 2002.
14. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, Lee YS, Bhowmick DA, Lubensky IA, Oldfield EH and Zhuang Z: Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23: 6806-6814, 2004.
15. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J and Ushio Y: Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95: 249-257, 2002.
16. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC and Lo KW: Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58: 120-128, 1999.
17. Kleihues P, Schauble B, zur HA, Esteve J and Ohgaki H: Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150: 1-13, 1997.
18. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
19. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
20. Louis DN, Rubio MP, Correa KM, Gusella JF and von Deimling A: Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52: 507-515, 1993.
21. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P and Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530, 1997.
22. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL and Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8: 655-667, 1998.
23. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W and Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992.
24. Sembritzki O, Hagel C, Lamszus K, Deppert W and Bohn W: Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein. Neuro-oncol 4: 171-178, 2002.
25. Rubio MP, von Deimling A, Yandell DW, Wiestler OD, Gusella JF and Louis DN: Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467, 1993.
26. Elledge RM, Clark GM, Chamness GC and Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712, 1994.
27. Prives C and Manfredi JJ: The continuing saga of p53 - more sleepless nights ahead. Mol Cell 19: 719-721, 2005.
28. Almog N and Rotter V: An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. Biochim Biophys Acta 1378: R43-R54, 1998.
29. Akyuz N, Boehden GS, Susse S, Rimek A, Preuss U, Scheidtmann KH and Wiesmuller L: DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 22: 6306-6317, 2002.
30. Sarkar C, Sinha S, Sharma MC, Kumar R and Mehta VS: Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation. Brain Tumor Pathol 21: 7-12, 2004.
31. Peraud A, Kreth FW, Wiestler OD, Kleihues P and Reulen HJ: Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8: 1117-1124, 2002.
32. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB and Aldape KD: Aberrant p53, mdm2, and proliferation differ in glioblastomas from longterm compared with typical survivors. Clin Cancer Res 8: 180-187, 2002.
33. Kraus A, Gross MW, Knuechel R, Munkel K, Neff F and Schlegel J: Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53. J Neurosurg 93: 863-872, 2000.
34. Chozick BS, Pezzullo JC, Epstein MH and Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 55: 831-837, 1994.
35. Sarkar C, Ralte AM, Sharma MC and Mehta VS: Recurrent astrocytic tumours - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16: 335-342, 2002.
36. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J and Weller M: Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J Neurooncol 39: 19-32, 1998.
37. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, and Oldfield EH: Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 54: 1-5, 1994.
38. Sabapathy K, Klemm M, Jaenisch R and Wagner EF: Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 16: 6217-6229, 1997.
39. van Lookeren CM and Gill R: Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: comparison with expression of the cell cycle regulators p21Waf1/Cip1, p27Kip1, p57Kip2, p16Ink4a, cyclin G1, and the proto-oncogene Bax. J Comp Neurol 397: 181-198, 1998.
40. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V and Schwartz M: p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16: 5178-5185, 1996.
41. Stagaard M and Mollgard K: The developing neuroepithelium in human embryonic and fetal brain studied with vimentin-immunocytochemistry. Anat Embryol (Berl) 180: 17-28, 1989.
42. Cosgrove M, Fitzgibbons PL, Sherrod A, Chandrasoma PT and Martin SE: Intermediate filament expression in astrocytic neoplasms. Am J Surg Pathol 13: 141-145, 1989.
43. Dahlstrand J, Collins VP and Lendahl U: Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52: 5334-5341, 1992.
44. Goldman SC, Chen CY, Lansing TJ, Gilmer TM and Kastan MB: The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 148: 1381-1385, 1996.
45. Pipas JM and Levine AJ: Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 11: 23-30, 2001.
46. Andrews P, He YJ and Xiong Y: Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 2006.
47. Kaul SC, Aida S, Yaguchi T, Kaur K and Wadhwa R: Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 280: 39373-39379, 2005.
48. Mukhopadhyay D, Tsiokas L and Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
49. Miyagami M and Katayama Y: Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 38: 36-42, 2005.
50. Plate KH and Risau W: Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995.